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Abstract 
Aims: The aim of this study was to investigate the association of four single nucleotide polymorphisms (SNPs) of 
peroxisome proliferator-activated receptor gamma (PPARG) with type 2 diabetes mellitus (T2DM) risk and additional 
role of gene-obesity interaction.
Methods: Four SNPs were selected for genotyping in the case–control study: rs1805192, rs709158, rs3856806 and 
rs4684847. Generalized multifactor dimensionality reduction (GMDR) model and logistic regression was used to 
examine the interaction between SNP and obesity on T2DM, odds ratio (OR) and 95% confident interval (95% CI) were 
calculated.
Results: T2DM risk was significantly higher in individuals with rs1805192-G allele (p < 0.05). The carriers of G allele of 
the rs1805192 polymorphism revealed increased T2DM risk than those with CC variants (CG + GG versus CC, adjusted 
OR (95% CI) 1.76 (1.45–2.06), p < 0.001). T2DM risk was also significantly higher in individuals with rs3856806-T allele 
(p < 0.05). The carriers of T allele of the rs3856806 polymorphism revealed increased T2DM risk than those with CC 
variants (CT + TT versus CC, adjusted OR (95% CI) 1.25 (1.17–1.76), p < 0.001). There was a significant two-locus model 
(p = 0.0107) involving rs1805192 and obesity. Obese subjects with CG or GG genotype have the highest T2DM risk, 
compared to subjects with CC genotype and normal BMI (OR 2.40, 95% CI 1.68–3.63).
Conclusions: Our results support an important association between rs1805192 and rs3856806 minor allele (G 
allele) of PPARG and increased T2DM risk, the interaction analysis shown a combined effect of G- obesity interaction 
between rs1805192 and obesity on increased T2DM risk.
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Background
Diabetes mellitus (DM) is a group of common metabolic 
disorders that share the phenotype of hyperglycemia. 
Globally, about 5.4% of adult population has been esti-
mated to have type 2 diabetes mellitus (T2DM) [1]. Sev-
eral types of diabetes mellitus exist and are caused by a 
complex interaction of genetics and environmental fac-
tors [2]. Type 2 diabetes has a strong genetic component. 
There is evidence that the Pro12Ala polymorphism is 
linked to obesity and T2DM [3].
The peroxisome proliferator-activated receptor gamma 
(PPARG) is now recognized to play a main PPARG 
entered the spotlight as a major player in metabolic 
regulation in the early 1990s [4] through the discov-
ery of thiazolidinediones (TZDs) as potent synthetic 
insulin-sensitizing drugs. TZDs quickly passed clinical 
trials and became front-line agents in the treatment of 
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glucose-lowering actions, although their popularity has 
recently decreased in response to safety concerns. Acti-
vation of PPARG results in systemic insulin sensitiza-
tion through complex mechanisms involving multiple. 
PPARG was the first gene reproducibly associated with 
T2DM. The association between the substitution of ala-
nine by proline at codon 12 of PPARG2 (Ala12 allele) 
and the risk for T2DM has been widely studied since Yen 
et al. [5], first reported this polymorphism. Some studies 
indicated that rs1805192 SNP plays a key role in regulat-
ing the expression of numerous genes involved in lipid 
metabolism, metabolic syndrome, inflammation, and 
atherosclerosis [6, 7]. Some environmental risk factors 
for T2DM were suggested, such as obesity, which was 
reported in different populations [8–10]. However, till 
now, no study focused on the impact of gene- environ-
ment interaction between PPARG and obesity on T2DM 
risk in Chinese population. So the aim of this study was 
to investigate the association of PPARG, and additional 
PPARG gene- obesity interaction with T2DM risk based 
on a Chinese population.
Methods
Subjects
This was a case–control study. Chinese patients with 
T2DM were consecutively recruited between January 
2012 and December 2013 from the Shenzhen Futian Dis-
trict traditional Chinese medicine hospital. A total of 
1297 subjects consist of 647 T2DM patients and 650 nor-
mal controls were included in this study, including 606 
males and 691 females. The mean age of all subjects was 
54.3  ±  15.8  years old. The selected subjects were simi-
lar to those who were not selected in terms of age, sex, 
smoking status and alcohol consumption. Informed con-
sent was obtained from all participants.
Body measurements
Data on general demographic information and lifestyle 
information for all participants were obtained using a 
standard questionnaire administered by trained staffs. 
Body weight, height and waist circumference (WC) was 
measured, and body mass index (BMI) was calculated as 
weight in kilograms divided by the square of the height in 
meters. Cigarette smokers were those who self-reported 
smoking cigarettes at least once a day for 1 year or more 
[11]. Alcohol consumption was expressed as the sum of 
milliliters of alcohol per week from wine, beer, and spirits 
[12]. Blood samples were collected in the morning after 
at least 8 h of fasting. All plasma and serum samples were 
frozen at −80 °C until laboratory testing. Plasma glucose 
was measured using an oxidase enzymatic method. Con-
centrations of high-density lipoprotein (HDL)-choles-
terol and triglyceride (TG) were assessed enzymatically 
by an automatic biochemistry analyzer (Hitachi Inc, 
Tokyo, Japan) using commercial reagents. All analysis 
was performed by the same lab.
Genomic DNA extraction and genotyping
We selected SNPs within PPARG according to the follow-
ing methods: (1) more studied SNPs, such as rs1805192, 
which was more studied in previous studies; (2) we also 
selected the others SNP of PPARG, in order to find new 
SNP associated with T2DM in Chinese population. 
Four SNPs were selected for genotyping in this study: 
rs1805192, rs709158, rs3856806, rs4684847. Four SNPs 
were detected by Taqman fluorescence probe, and probe 
sequences of four SNPs were shown in Table 1. Genomic 
DNA from participants was extracted from EDTA-
treated whole blood, using the DNA Blood Mini Kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s 
instructions. ABI Prism7000 software and allelic dis-
crimination procedure was used for genotyping of fore-
mentioned four SNPs. A 25 μl reaction mixture including 
1.25 μl SNP Genotyping Assays (20×), 12.5 μl Genotyp-
ing Master Mix (2×), 20  ng DNA, and the conditions 
were as follows: initial denaturation for 10 min and 95 °C, 
denaturation for 15 s and 92 °C, annealing and extension 
for 90 s and 60 °C, 50 cycles.
Diagnostic criteria
Diagnosis of diabetes at baseline for a fasting glucose 
was ≥126 mg/dl (7.0 mmol/l) or if hypoglycemic therapy 
(oral agents or insulin) had been executed. During the fol-
low-up, the criteria for the diagnosis of T2DM included a 
fasting glucose ≥126 mg/dl (7.0 mmol/l), or a 2 h post-
prandial blood glucose ≥200  mg/dl (11.0  mmol/l), or if 
hypoglycemic therapy (oral agents or insulin) had been 
started in the interim [13].
Obesity was defined by using WHO criteria for Asian 
populations: BMI value ≥ 28 kg/m2 [14].
Statistical analysis
The means and SD (standard deviation) was calculated 
for normally distributed continuous variables, and com-
pared using t test. Percentages were calculated for cate-
gorical variable, and compared between case and control 
group participants using a Chi square test. Genotype and 
allele frequencies were obtained by direct count. Geno-
type distributions in T2DM patients and controls were 
evaluated by χ2 test using SPSS (version 19.0; SPSS Inc., 
Chicago, IL). Hardy–Weinberg equilibrium (HWE) was 
performed by using SNPStats (available online at http://
bioinfo.iconcologia.net/SNPstats). Logistic regression 
model was used to examine the interaction between SNP 
and obesity on T2DM in additive model, odds ratio (OR) 
and 95% confident interval (95% CI) were calculated. 
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Odds were adjusted for gender, age, smoke and alco-
hol status, high fat diet, low fiber diet, TC, TG and 
HDL. Generalized multifactor dimensionality reduction 
(GMDR) [15] was used to investigate the gene- environ-
ment interaction, cross-validation consistency, the test-
ing balanced accuracy, and the sign test, to assess each 
selected interaction were calculated. The cross-validation 
consistency score is a measure of the degree of consist-
ency with which the selected interaction is identified 
as the best model among all possibilities considered. 
Testing-balanced accuracy is a measure of the degree 
to which the interaction accurately predicts case–con-
trol status, and yields a score between 0.50 (indicating 
that the model predicts no better than chance) and 1.00 
(indicating perfect prediction). Finally, the sign test, or 
permutation test (providing empirical p values), for pre-
diction accuracy can be used to measure the significance 
of an identified model.
Results
A total of 1297 subjects including 647 T2DM patients 
and 650 normal controls were included in this study, 
including 606 males and 691 females. The mean age of all 
subjects was 54.3 ±  15.8  years old. Participants charac-
teristics stratified by T2DM cases and controls are shown 
in Table 2. The distributions of males, smoking, alcohol 
consumption, high fat diet, low fiber diet and mean of 
age were not different between cases and controls. The 
means of BMI, WC, TG, TC and HDL were significantly 
different between cases and controls.
All genotypes were distributed according to Hardy–
Weinberg equilibrium (all p values were more than 0.05). 
There were significant differences in rs1805192 and 
rs3856806 alleles and genotypes distributions between 
cases and controls (Table  3). The frequency for G allele 
of rs1805192 was higher in cases (49.0% in T2DM 
patients and 37.5% in controls, p < 0.001). Logistic analy-
sis showed that T2DM risk was significantly higher in 
individuals with rs1805192-G allele (p  <  0.05). The car-
riers of G allele of the rs1805192 polymorphism revealed 
increased T2DM risk than those with CC variants 
(CG + GG versus CC, adjusted OR (95% CI) 1.76 (1.45–
2.06), p < 0.001). The frequency for T allele of rs3856806 
was higher in cases (50.2% in T2DM patients and 38.9% 
in controls, p  <  0.001). Logistic analysis showed that 
T2DM risk was significantly higher in individuals with 
rs3856806-T allele (p  <  0.05). The carriers of T allele of 
the rs3856806 polymorphism revealed increased T2DM 
risk than those with CC variants (CT + TT versus CC, 
adjusted OR (95% CI) 1.25 (1.17–1.76), p < 0.001). How-
ever, we did not find any significant association between 
other two SNPs and T2DM risk before or after covariates 
adjustment.
We employed the GMDR analysis to assess the impact 
of the PPARG gene- obesity interaction on T2DM risk, 
after adjustment for gender, age, smoke and alcohol con-
sumption status, high fat diet, low fiber diet, TC and 
HDL. Table  4 summarizes the results obtained from 
GMDR analysis for two- to five-locus models. There 
was a significant two-locus model (p  =  0.0107) involv-
ing rs1805192 and obesity, indicating a potential gene–
environment interaction among rs1805192 and obesity. 
Overall, the two- locus models had a cross-validation 
consistency of 10 of 10, and had the testing accuracy of 
62.17%.
In order to obtain the odds ratios and 95% CI for the 
joint effects of rs1805192 genotype and obesity on 
T2DM, we conducted interaction analysis between 
rs1805192 and obesity. We found that obese subjects 
with CG or GG genotype have the highest T2DM risk, 
compared to subjects with CC genotype and normal BMI 
(OR 2.40, 95% CI 1.68–3.63), after adjustment for gen-
der, age, smoke and alcohol status, high fat diet, low fiber 
diet, TC and HDL (Table 5).
Discussion
The result of this study indicated that rs1805192- G 
allele and rs3856806-T allele of PPARG is significantly 
associated with higher T2DM risk, however, we did 
not find any association between the others SNPs and 
Table 1 Probe sequence for four SNPs used for Taqman fluorescence probe analysis
SNP Rs number Chromosome Functional consequence Position Probe sequence
C1341T rs3856806 3 Intron variant 12,415,557 5′-GGTTGACACAGAGATGCCATTCTGG[C/G]
CCACCAACTTTGGGATCAGCTCCGT-3′
Intron A>G rs709158 3 Intron variant 12,403,176 5′-AGATACGGGGGAGGAAATTCACTGG[A/G]
TTTTACAATATATTTTTCAAGGCAA-3′
Pro12Ala rs1805192 3 Missense 12,361,238 5′-ACCTCAGACAGATTGTCACGGAACA[C/T]
GTGCAGCTACTGCAGGTGATCAAGA-3′
Intron C>T rs4684847 3 Intron variant 12,326,337 5′-ATTTATTTAAATCATCTCTAATTCT[C/T]
ACAACTCCGAAAAGATAAGAAAACA-3′
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T2DM. Although many studies have taken a candi-
date gene approach to investigate the genetic etiology 
of T2DM, implicating the potential candidate genes in 
T2DM risk factors, which include genes for rs1805192 
and rs3856806 polymorphism of PPARG [16], however 
the results of association between rs1805192 and T2DM 
are inconsistent. Wang et al. [17] demonstrated that the 
presence of the Ala allele may contribute to improved 
Table 2 General characteristics of study participants in T2DM case and control group
Median and inter quartile for TG; mean ± standard deviation for age, FPG, TC, HDL-C
TC total cholesterol, HDL high density lipoprotein, FPG fast plasma glucose, TG triglyceride
Variables T2DM cases group (n = 647) Control group (n = 650) p values
Age (years) 56.7 ± 14.8 55.4 ± 14.2 0.107
Males N (%) 310 (47.9) 296 (45.5) 0.391
Smoke N (%) 153 (23.6) 174 (26.8) 0.257
Alcohol consumption N (%) 144 (22.2) 136 (20.9) 0.559
High fat diet N (%) 106 (16.4) 114 (17.5) 0.579
Low fiber diet N (%) 118 (18.2) 96 (14.8) 0.092
WC (cm) 89.1 ± 15.8 86.8 ± 16.5 0.010
BMI (kg/m2) 25.8 ± 6.8 23.3 ± 6.6 <0.001
TG (mmol/l) 2.1 ± 0.67 1.8 ± 0.70 <0.001
TC (mmol/l) 5.3 ± 1.2 4.7 ± 1.1 <0.001
HDL (mmol/l) 1.21 ± 0.33 1.32 ± 0.27 <0.001
Table 3 Genotype and allele frequencies of four SNPs between T2DM case and control group
a Adjusted for gender, age, smoke and alcohol consumption status, high fat diet, low fiber diet, TC and HDL
SNPs Genotypes and Alleles Frequencies N(%) OR (95% CI)a p values HWE test
Case (n = 647) Control (n = 650)
rs3856806 CC 322 (49.8) 397 (61.1) 1.00 <0.001 0.379
CT 256 (39.6) 217 (33.4) 1.12 (1.06–1.58)
TT 69 (10.7) 36 (5.5) 1.93 (1.34–2.71)
CT + TT 325 (50.2) 253 (38.9) 1.25 (1.17–1.76) <0.001
C 900 (69.6) 1011 (77.8) <0.001
T 394 (30.4) 289 (22.2)
rs709158 AA 341 (52.7) 373 (57.4) 1.00 0.128 0.165
AG 243 (37.6) 230 (35.4) 1.06 (0.95–1.37)
GG 63 (9.7) 47 (7.2) 1.10 (0.86–1.61)
AG + GG 306 (47.3) 277 (42.6) 1.07 (0.92–1.43) 0.090
A 925 (71.5) 976 (75.1) 0.039
G 369 (28.5) 324 (24.9)
rs1805192 CC 330 (51.0) 406 (62.5) 1.00 <0.001 0.385
CG 262 (40.5) 220 (33.8) 1.42 (1.61–1.84)
GG 55 (8.5) 24 (3.7) 2.13 (1.72–2.93)
CG + GG 317 (49.0) 244 (37.5) 1.76 (1.45–2.06) <0.001
C 922 (71.2) 1032 (79.4) <0.001
G 372 (28.8) 268 (20.6)
rs4684847 CC 346 (53.5) 379 (58.3) 1.00 0.203 0.277
CT 250 (38.6) 228 (35.1) 1.08 (0.91–1.36)
TT 51 (7.9) 43 (6.6) 1.04 (0.82–1.53)
CT + TT 301 (46.5) 271 (41.7) 1.07 (0.89–1.39) 0.080
C 942 (72.8) 986 (75.8) 0.076
T 352 (27.2) 314 (24.2)
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insulin secretory capacity and may confer protection 
from T2DM and obesity in the Chinese population. 
Moreover, a meta-analysis confirmed the association 
between the PPARG2 Pro12 allele and T2DM, and sug-
gested that patients who carry the Pro12 allele have a 
1.27-fold higher risk for developing T2DM than Ala12 
carriers. This seemingly modest effect translates into 
a staggering 25% population-attributable risk because 
of the higher frequency of the Pro12 allele, especially 
in Japanese and European populations [18]. However, 
Bener et al. [19] suggested that no significant association 
between the Pro12Ala polymorphism of the PPARG2 
gene and T2DM in Qatari’s population. Al-Safar et  al. 
[20] also suggested that confirmed that Pro12Ala muta-
tion in PPARG2 is not associated with T2DM risk in this 
population. In a study for South Africa population, Ver-
gotine et al. [21] reported that the Pro12Ala of PPARG2 
is significantly associated with insulin resistance and 
this polymorphism interacts with IRS1 Gly972Arg, to 
increase the risk of T2DM. Hahn et  al. [22] indicated 
that our data confirm a beneficial effect of the PPARG1 
12Ala allele on insulin resistance and glucose metabolism 
in PCOS women. Furthermore, the Ala allele appears to 
be associated with less severe hirsutism, independent 
of hyperandrogenemia. Tellechea et  al. [23] conducted 
a study for males of Argentinian blood donors of self-
reported European ancestry and indicated that healthy 
men, in particular nonsmokers, carrying the Ala12 allele 
of PPARG rs1801282 polymorphism, have a high risk 
for metabolic syndrome (MetS) and insulin resistance 
(IR). Fan et  al. [24] indicated that the genotypes with 
minor allele variants at the rs1805192, rs709158 and 
rs3856806 loci are associated with increased LDL-C lev-
els, which was a risk factor of T2DM. Gu et al. [25] also 
suggested that in the codominant and log-additive mod-
els, rs1805192 and rs3856806 were all associated with 
increased dyslipidemia risk. A study conducted by Phani 
et  al. [26] showed that PPARG2 variants are associated 
with increased T2DM susceptibility when associated 
with adiposity in Indian population. These data reflect 
an association of analyzed PPARG gene polymorphisms 
with values of insulin, HDL, LDL and total cholesterol 
which indicates an important role of these genes in lipid 
metabolism and pathogenesis of T2DM and MetS [16].
T2DM is associated with both environmental and 
genetic factors. Several metabolic abnormalities are 
implicated in its pathogenesis, such as obesity and other 
environmental factors. Several studies have confirmed 
the association between obesity and T2DM. However, till 
now, no study focused on impact of gene-environment 
interaction between PPARG and obesity on T2DM risk 
in Chinese population. This study investigated the impact 
of additional PPARG gene-obesity interaction on T2DM 
risk based on a Chinese population by using GMDR 
model. We found that a significant two-locus model 
involving rs1805192 and obesity, indicating a potential 
gene-environment interaction among rs1805192 and 
obesity. Obese subjects with CG or GG genotype have 
the highest T2DM risk, compared to subjects with CC 
genotype and normal BMI.
Several limitations of this study should be considered. 
Firstly, More SNPs of PPARG gene should been chosen. 
The limited SNPs were not sufficient to capture most 
genetic information of PPARG. Secondly, there was a rel-
atively small sample size in the study, other larger sample 
studies should be conducted in the future. Thirdly, we did 
not obtain any information on IR level.
Conclusions
Our results support an important association between 
rs1805192 and rs3856806 minor allele (G allele) of 
PPARG and increased T2DM risk, the interaction anal-
ysis shown a combined effect of G- obesity interaction 
between rs1805192 and obesity on increased T2DM risk.
Table 4 Best gene- obesity interaction models, as identified by GMDR
* Adjusted for gender, age, smoke and alcohol consumption status, high fat diet, low fiber diet, TC and HDL
Locus no. Best combination Cross-validation consistency Testing accuracy p values*
2 rs1805192 Obesity 10/10 0.6217 0.0107
3 rs1805192 rs3856806 Obesity 9/10 0.5577 0.1719
4 rs1805192 rs3856806 rs709158 Obesity 8/10 0.5590 0.0547
5 rs1805192 rs3856806 rs709158 rs4684847 Obesity 7/10 0.4958 0.3770
Table 5 Interaction analysis for  rs1805192 and  obesity 
on T2DM by using logistic regression
a Adjusted for gender, age, smoke and alcohol consumption status, high fat 
diet, low fiber diet, TC and HDL
Rs1805192 Obesity OR (95% CI)a p values
CC No 1.00 –
CG or GG No 1.21 (1.08–1.47) 0.020
CC Yes 1.52 (1.13–1.93) <0.001
CG or GG Yes 2.40 (1.68–3.63) <0.001
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